Effects of Compounds Isolated from Lindera erythrocarpa on Anti-Inflammatory and Anti-Neuroinflammatory Action in BV2 Microglia and RAW264.7 Macrophage.
Chi-Su YoonHwan LeeZhiming LiuHyeong-Kyu LeeDong Sung LeePublished in: International journal of molecular sciences (2022)
Lindera erythrocarpa contains various constituents such as cyclopentenedione-, flavonoid-, and chalcone-type components. In this study, a novel bi-linderone derivative and 17 known compounds were isolated from the leaves of L. erythrocarpa by using various chromatographic methods. The structures of the components were determined from nuclear magnetic resonance and mass spectrometry data. All isolated compounds were tested for anti-inflammatory and anti-neuroinflammatory activities in lipopolysaccharide (LPS)-induced BV2 and RAW264.7 cells. Some of these compounds showed anti-inflammatory effects by inhibiting the nitric oxide (NO) produced by LPS. In particular, linderaspirone A ( 16 ), bi-linderone ( 17 ) and novel compound demethoxy-bi-linderone ( 18 ) showed significant inhibitory effects on the production of prostaglandin E2 (PGE 2 ), tumor necrosis factor-α, and interleukin-6. The three compounds also inhibited the expression of inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2), which are pro-inflammatory proteins, and the activation of nuclear factor κB (NF-κB). Therefore, linderaspirone A ( 16 ), bi-linderone ( 17 ), and demethoxy-bi-linderone ( 18 ) isolated from the leaves of L. erythrocarpa have therapeutic potential in neuroinflammatory diseases.
Keyphrases
- lps induced
- inflammatory response
- anti inflammatory
- nuclear factor
- toll like receptor
- magnetic resonance
- nitric oxide
- lipopolysaccharide induced
- mass spectrometry
- signaling pathway
- nitric oxide synthase
- induced apoptosis
- poor prognosis
- rheumatoid arthritis
- high resolution
- computed tomography
- spinal cord injury
- immune response
- magnetic resonance imaging
- high performance liquid chromatography
- binding protein
- cell proliferation
- pi k akt